Here are three things to know:
1. The round included $3.9 million in equity and a $2 million credit facility.
2. Bone Biologics will use the proceeds for working capital, protein development, regulatory and clinical expenses and to repay $600,000 in debt.
3. The company is developing the recombinant human protein growth factor NELL-1 bone graft substitute for spinal fusion.
More articles on biologics:
Viscogliosi Brothers to purchase Bioventus’ BMP development program: 5 insights
3 things to know about Ortho RTi
23 developments in spine & orthopedic biologics research in 2018
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
